Keyword: Vraylar

Allergan's best-selling Botox and other promising meds may not be enough to fill the Humira gap. What could help? Hiving off assets, one analyst says.

AbbVie hopes its Allergan takeover will help it weather the storm of an aging Humira. Could the next-gen antipsychotic Vraylar be a solution?

With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.

Allergan depicts the ups and downs of bipolar disorder with an elevator metaphor in its newest Vraylar ad campaign.

Allergan, badly in need of good news, finally has some to share with investors who've been clamoring for change.

With three quarters of pharma TV ad spending down and one to go, national media buys are tracking ahead of 2017, with brands doling out $2.81 billion.

​​​​​​​Allergan’s new campaign for Vraylar is the antipsychotic's first—and the first DTC push to center on the manic side of bipolar disorder.

Allergan says CFO Tessa Hilado, which came to Allergan three years ago, is retiring but agreed to stay on until her replacement is named.

Allergan may be able to come up big with new antipsychotic launch Vraylar if the med can shine at treating schizophrenia’s “negative” symptoms. But one analyst isn’t holding his breath.